Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Sell
49
QGEN Quote, Financials, Valuation and Earnings
Last price:
$45.01
Seasonality move
:
7.54%
Day range:
$44.70 - $45.23
52-week range:
$39.03 - $47.44
Dividend yield:
0%
P/E ratio:
110.64x
P/S ratio:
5.01x
P/B ratio:
2.83x
Volume:
444.9K
Avg. volume:
839K
1-year change:
0.37%
Market cap:
$10B
Revenue:
$2B
EPS (TTM):
$0.41
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$491.1M | $0.55 | 1.95% | 39.42% | $51.26 |
|
HAE
Haemonetics
|
$342.6M | $1.07 | 5.26% | 92.62% | $110.80 |
|
LENZ
LENZ Therapeutics
|
-- | -$0.43 | -- | -57.13% | -- |
|
MRUS
Merus NV
|
$8.7M | -$0.85 | -4.27% | -10.77% | $86.07 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.32 | -- | -29.53% | $43.17 |
|
QURE
uniQure NV
|
$7.1M | -$1.01 | 194.09% | -62.87% | $30.72 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$44.99 | $51.26 | $10B | 110.64x | $1.28 | 0% | 5.01x |
|
HAE
Haemonetics
|
$77.57 | $110.80 | $3.9B | 32.19x | $0.00 | 0% | 2.93x |
|
LENZ
LENZ Therapeutics
|
$31.32 | -- | $861.3M | -- | $0.00 | 0% | -- |
|
MRUS
Merus NV
|
$42.07 | $86.07 | $2.9B | -- | $0.00 | 0% | 72.01x |
|
ORKA
Oruka Therapeutics
|
$19.01 | $43.17 | $665.3M | -- | $0.00 | 0% | -- |
|
QURE
uniQure NV
|
$17.50 | $30.72 | $853M | -- | $0.00 | 0% | 29.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QGEN
Qiagen NV
|
35.23% | 0.468 | 18.96% | 1.62x |
|
HAE
Haemonetics
|
58.23% | 0.561 | 30.25% | 1.87x |
|
LENZ
LENZ Therapeutics
|
-- | 3.332 | -- | -- |
|
MRUS
Merus NV
|
-- | 1.520 | -- | 7.94x |
|
ORKA
Oruka Therapeutics
|
-- | 0.000 | -- | -- |
|
QURE
uniQure NV
|
47.8% | 0.153 | 21.27% | 6.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$308.3M | $120.8M | 1.8% | 2.58% | 25.49% | $138M |
|
HAE
Haemonetics
|
$187.4M | $51.7M | 6.54% | 13.51% | 14.96% | $39.4M |
|
LENZ
LENZ Therapeutics
|
-- | -$12.9M | -- | -- | -- | -$10.8M |
|
MRUS
Merus NV
|
-- | -$72.2M | -47.97% | -47.97% | -613.59% | -$80.7M |
|
ORKA
Oruka Therapeutics
|
-- | -$29.4M | -- | -- | -- | -- |
|
QURE
uniQure NV
|
$1.3M | -$40.2M | -96.96% | -154.29% | -1215.48% | -$45.3M |
Qiagen NV vs. Competitors
-
Which has Higher Returns QGEN or HAE?
Haemonetics has a net margin of 19.54% compared to Qiagen NV's net margin of 9.79%. Qiagen NV's return on equity of 2.58% beat Haemonetics's return on equity of 13.51%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B HAEHaemonetics54.25% $0.66 $2.1B -
What do Analysts Say About QGEN or HAE?
Qiagen NV has a consensus price target of $51.26, signalling upside risk potential of 13.94%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 42.84%. Given that Haemonetics has higher upside potential than Qiagen NV, analysts believe Haemonetics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 6 0 HAEHaemonetics3 2 0 -
Is QGEN or HAE More Risky?
Qiagen NV has a beta of 0.351, which suggesting that the stock is 64.89% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.
-
Which is a Better Dividend Stock QGEN or HAE?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or HAE?
Qiagen NV quarterly revenues are $501.9M, which are larger than Haemonetics quarterly revenues of $345.5M. Qiagen NV's net income of $98.1M is higher than Haemonetics's net income of $33.8M. Notably, Qiagen NV's price-to-earnings ratio is 110.64x while Haemonetics's PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.01x versus 2.93x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.01x 110.64x $501.9M $98.1M HAEHaemonetics2.93x 32.19x $345.5M $33.8M
-
Which has Higher Returns QGEN or LENZ?
LENZ Therapeutics has a net margin of 19.54% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.58% beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B LENZLENZ Therapeutics-- -$0.38 -- -
What do Analysts Say About QGEN or LENZ?
Qiagen NV has a consensus price target of $51.26, signalling upside risk potential of 13.94%. On the other hand LENZ Therapeutics has an analysts' consensus of -- which suggests that it could grow by 25.43%. Given that LENZ Therapeutics has higher upside potential than Qiagen NV, analysts believe LENZ Therapeutics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 6 0 LENZLENZ Therapeutics0 0 0 -
Is QGEN or LENZ More Risky?
Qiagen NV has a beta of 0.351, which suggesting that the stock is 64.89% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or LENZ?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or LENZ?
Qiagen NV quarterly revenues are $501.9M, which are larger than LENZ Therapeutics quarterly revenues of --. Qiagen NV's net income of $98.1M is higher than LENZ Therapeutics's net income of -$10.2M. Notably, Qiagen NV's price-to-earnings ratio is 110.64x while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.01x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.01x 110.64x $501.9M $98.1M LENZLENZ Therapeutics-- -- -- -$10.2M
-
Which has Higher Returns QGEN or MRUS?
Merus NV has a net margin of 19.54% compared to Qiagen NV's net margin of -848.67%. Qiagen NV's return on equity of 2.58% beat Merus NV's return on equity of -47.97%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B MRUSMerus NV-- -$1.46 $703.3M -
What do Analysts Say About QGEN or MRUS?
Qiagen NV has a consensus price target of $51.26, signalling upside risk potential of 13.94%. On the other hand Merus NV has an analysts' consensus of $86.07 which suggests that it could grow by 104.59%. Given that Merus NV has higher upside potential than Qiagen NV, analysts believe Merus NV is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 6 0 MRUSMerus NV12 0 0 -
Is QGEN or MRUS More Risky?
Qiagen NV has a beta of 0.351, which suggesting that the stock is 64.89% less volatile than S&P 500. In comparison Merus NV has a beta of 1.071, suggesting its more volatile than the S&P 500 by 7.125%.
-
Which is a Better Dividend Stock QGEN or MRUS?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or MRUS?
Qiagen NV quarterly revenues are $501.9M, which are larger than Merus NV quarterly revenues of $11.8M. Qiagen NV's net income of $98.1M is higher than Merus NV's net income of -$99.9M. Notably, Qiagen NV's price-to-earnings ratio is 110.64x while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.01x versus 72.01x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.01x 110.64x $501.9M $98.1M MRUSMerus NV72.01x -- $11.8M -$99.9M
-
Which has Higher Returns QGEN or ORKA?
Oruka Therapeutics has a net margin of 19.54% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.58% beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B ORKAOruka Therapeutics-- -$1.46 -- -
What do Analysts Say About QGEN or ORKA?
Qiagen NV has a consensus price target of $51.26, signalling upside risk potential of 13.94%. On the other hand Oruka Therapeutics has an analysts' consensus of $43.17 which suggests that it could grow by 127.07%. Given that Oruka Therapeutics has higher upside potential than Qiagen NV, analysts believe Oruka Therapeutics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 6 0 ORKAOruka Therapeutics6 0 0 -
Is QGEN or ORKA More Risky?
Qiagen NV has a beta of 0.351, which suggesting that the stock is 64.89% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or ORKA?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or ORKA?
Qiagen NV quarterly revenues are $501.9M, which are larger than Oruka Therapeutics quarterly revenues of --. Qiagen NV's net income of $98.1M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, Qiagen NV's price-to-earnings ratio is 110.64x while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.01x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.01x 110.64x $501.9M $98.1M ORKAOruka Therapeutics-- -- -- -$28.6M
-
Which has Higher Returns QGEN or QURE?
uniQure NV has a net margin of 19.54% compared to Qiagen NV's net margin of -1940.45%. Qiagen NV's return on equity of 2.58% beat uniQure NV's return on equity of -154.29%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B QUREuniQure NV55.36% -$0.91 $106.9M -
What do Analysts Say About QGEN or QURE?
Qiagen NV has a consensus price target of $51.26, signalling upside risk potential of 13.94%. On the other hand uniQure NV has an analysts' consensus of $30.72 which suggests that it could grow by 75.56%. Given that uniQure NV has higher upside potential than Qiagen NV, analysts believe uniQure NV is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 6 0 QUREuniQure NV8 2 0 -
Is QGEN or QURE More Risky?
Qiagen NV has a beta of 0.351, which suggesting that the stock is 64.89% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.895, suggesting its less volatile than the S&P 500 by 10.539%.
-
Which is a Better Dividend Stock QGEN or QURE?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or QURE?
Qiagen NV quarterly revenues are $501.9M, which are larger than uniQure NV quarterly revenues of $2.3M. Qiagen NV's net income of $98.1M is higher than uniQure NV's net income of -$44.4M. Notably, Qiagen NV's price-to-earnings ratio is 110.64x while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.01x versus 29.62x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.01x 110.64x $501.9M $98.1M QUREuniQure NV29.62x -- $2.3M -$44.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
